Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.35 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.35 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18791044 | 1.00 | CES2 (0.50) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL18791047 | 1.00 | CES2 (0.50) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL9011610 | 0.97 | CES2 (0.46) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL2759589 | 0.92 | CES2 (0.39) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL6141459 | 0.86 | — | — | |
| SCHEMBL24241265 | 0.78 | EPHX1 (0.33) | CES2CES1ALDH1A1EPHX1RECQL | |
| SCHEMBL8595527 | 0.77 | LMNA (0.43) | TSHRSMN1; SMN2 | |
| SCHEMBL8595532 | 0.77 | LMNA (0.43) | TSHRSMN1; SMN2 | |
| SCHEMBL18988346 | 0.75 | EPHX2 (0.32) | — | |
| SCHEMBL17308235 | 0.75 | EPHX1 (0.33) | EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250090500-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2025-03-20 | — | — | US | disclosed |
| US-12220401-B2 | Compounds useful as kinase inhibitors | LOXO ONCOLOGY, INC. (US) | 2025-02-11 | — | — | US | disclosed |
| US-11826351-B2 | Compounds useful as kinase inhibitors | LOXO ONCOLOGY INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230372298-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2023-11-23 | — | — | US | disclosed |
| US-11471441-B2 | Compounds useful as kinase inhibitors | LOXO ONCOLOGY INC. (US) | 2022-10-18 | — | — | US | disclosed |
| US-11440892-B2 | Substituted dihydrobenzoxazinones, dihydroquinolones, and methods of their use and synthesis | NORTHWESTERN UNIVERSITY (US) | 2022-09-13 | — | — | US | disclosed |
| CN-114716381-A | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114634447-A | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2022-06-17 | — | — | CN | disclosed |
| CN-114621146-A | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2022-06-14 | — | — | CN | disclosed |
| CN-114605327-A | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2022-06-10 | — | — | CN | disclosed |
| US-8580780-B2 | 6 substituted 2, 3,4,5 tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonist | ELI LILLY AND COMPANY (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120028961-A1 | 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist | ELI LILLY AND COMPANY (US) | 2012-02-02 | — | — | US | disclosed |
| US-6288077-B1 | 2-AZABICYCLO(3.1.0)HEXANE-1,2-DICARBOXYLIC AMIDE OR 2-AZABICYCLO(4.1.0)HEPTANE-1,2-DICARBOXYLIC AMIDE DERIVATIVE; TRYPSIN-LIKE SERINE PROTEASE INHIBITOR; ANTICOAGULANTS | ADIR ET COMPAGNIE (FR) | 2001-09-11 | — | — | US | disclosed |
| EP-0623103-B1 | PROCESS FOR PRODUCING TRIFLUOROMETHYL KETONES | HOECHST SCHERING AGREVO GMBH (DE) | 1997-09-03 | — | — | EP | disclosed |
| US-5608062-A | Process for preparing trifluoromethyl ketones | HOECHST SCHERING AGREVO GMBH (DE) | 1997-03-04 | — | — | US | disclosed |
| EP-0418362-B1 | TRIFLUOROMETHYLCYCLOHEXANE DERIVATIVES | MERCK PATENT GMBH (DE) | 1995-01-04 | — | — | EP | disclosed |
| US-5209868-A | Liquid crystal medium | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1993-05-11 | — | — | US | disclosed |
| EP-0418362-A1 | TRIFLUOROMETHYLCYCLOHEXANE DERIVATIVES. | MERCK PATENT GMBH (DE) | 1991-03-27 | — | — | EP | disclosed |
| WO-1990012073-A1 | TRIFLUOROMETHYLCYCLOHEXANE DERIVATIVES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1990-10-18 | — | — | WO | disclosed |
| US-4378366-A | HYPOTENSIVE AND CARDIOTONIC AGENTS; ADRENERGIC STIMULANTS | SCIENCE UNION ET CIE (FR) | 1983-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12220401-B2 | Compounds useful as kinase inhibitors | BTK, ABL1, LCK | CES2 2629/4885CES1 3013/4885HDAC8 1621/4885 |
| US-20250090500-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | CES2 2629/4885CES1 3013/4885HDAC8 1621/4885 |
| US-11826351-B2 | Compounds useful as kinase inhibitors | BTK, ABL1, LCK | CES2 2629/4885CES1 3013/4885HDAC8 1621/4885 |
| US-11471441-B2 | Compounds useful as kinase inhibitors | BTK, ABL1, LCK | CES2 2629/4885CES1 3013/4885HDAC8 1621/4885 |
| US-20230372298-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | CES2 2629/4885CES1 3013/4885HDAC8 1621/4885 |
| US-11440892-B2 | Substituted dihydrobenzoxazinones, dihydroquinolones, and methods of their use and synthesis | NQO1, DHPS, NQO2 | CES2 2037/4885CES1 1436/4885HDAC8 918/4885 |
| US-20120028961-A1 | 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist | HTR2C, HTR4, HTR1A | CES2 958/4885CES1 2224/4885HDAC8 3914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.